Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 14/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 14/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinalukast SCHEMBL37964 | 1.00 | KDM4E (1.00) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| SCHEMBL9330119 | 0.98 | KDM4E (0.97) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| SCHEMBL9328941 | 0.98 | KDM4E (0.97) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| SCHEMBL9796296 | 0.97 | KDM4E (0.95) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| SCHEMBL9796304 | 0.97 | KDM4E (0.95) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| SCHEMBL9328901 | 0.96 | KDM4E (0.93) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| SCHEMBL9328916 | 0.96 | KDM4E (0.93) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| Cinalukast SCHEMBL9331988 | 0.96 | KDM4E (0.92) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| Cinalukast SCHEMBL9331973 | 0.96 | KDM4E (0.92) | KDM4EMEN1ALDH1A1TP53ADRB1 | |
| Cinalukast SCHEMBL9331977 | 0.94 | KDM4E (0.88) | KDM4EMEN1ALDH1A1TP53ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 838 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2023075715-A1 | A PHARMACEUTICAL FORMULATION INCLUDING LEUKOTRIENE RECEPTOR ANTAGONISTS AND/OR LEUKOTRIENE SYNTHESIS INHIBITORS COMBINED WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) | VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI (TR) | 2023-05-04 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20220105082-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD (CN) | 2022-04-07 | — | — | US | claimed |
| EP-3908284-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | Jiangyin Mucocare Pharmaceutical Co., Ltd (CN) | 2021-11-17 | — | — | EP | claimed |
| WO-2020207165-A1 | COMPOUND FOR TREATING VASCULAR MALFORMATION | 中山大学附属第五医院 | 2020-10-15 | — | — | WO | claimed |
| WO-2020143744-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | JIANGYIN MUCOCARE PHARMACEUTICAL CO., LTD. (CN) | 2020-07-16 | — | — | WO | claimed |
| CN-110496124-A | The compound for treating vascular malformation | THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV | 2019-11-26 | — | — | CN | claimed |
| EP-2575786-B1 | PROCESS FOR DRY POWDER FORMULATIONS | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD STI (TR) | 2017-11-15 | — | — | EP | claimed |
| US-9259376-B2 | Process for dry powder formulations | SIMA PATENT VE LISANSLAMA HIZMETLERI LTD. STI. (TR) | 2016-02-16 | — | — | US | claimed |
| WO-2002000175-A2 | ENHANCING THERAPEUTIC EFFECTIVENESS OF NITRIC OXIDE INHALATION | THE GENERAL HOSPITAL CORPORATION (US) | 2002-01-03 | — | — | WO | claimed |
| WO-1996027592-A1 | POLYMORPHIC B FORM OF (E)-4-[[3-[2-(4-CYCLOBUTYL-2-THIAZOLYL)ETHENYL]PHENYL]AMINO]-2,2-DIETHYL-4-OXOBUTANOIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 1996-09-12 | — | — | WO | claimed |
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | claimed |
| EP-0662322-A2 | Pharmaceutical composition for controlled release | F. HOFFMANN-LA ROCHE AG (CH) | 1995-07-12 | — | — | EP | claimed |
| US-5393765-A | Includes hydroxypropyl methylcellulose; solubility; viscosity | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | claimed |
| EP-0355353-B1 | Cycloalkylthiazole derivatives | HOFFMANN LA ROCHE (CH) | 1994-03-16 | — | — | EP | claimed |
| US-5227378-A | Synergistic mixture of platelet activating factor and leukotriene antagonists | HOFFMANN-LA ROCHE INC. (US) | 1993-07-13 | — | — | US | claimed |
| EP-0469477-A1 | Antiallergic combination | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-05 | — | — | EP | claimed |
| US-5001140-A | Cycloalkylthiazoles | HOFFMANN-LA ROCHE INC. (US) | 1991-03-19 | — | — | US | claimed |
| EP-0355353-A2 | Cycloalkylthiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220105082-A1 | NEW FORMULATIONS CONTAINING LEUKOTRIENE RECEPTOR ANTAGONISTS | LTB4R, LTB4R2, CYSLTR1 | KDM4E 4333/4885MEN1 4822/4885ALDH1A1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.